ypeebrothers.com, for detailed information on cardiology books, visit our website www.jaypeebrothers.com, for detailed information on cardiology books

CARDIOLOGY

Examination Paper

for DM (Cardiology) Students



Barun Kumar

Foreword
Gurpreet S Wander

JAYPEE

Contents

Paper 4 (Set 1) Long-essay Questions and Answers 1
Short Questions and Answers 5

Paper 4 (Set 2) Long-essay Questions and Answers 15
Short Questions and Answers 19

Paper 4 (Set 3) Long-essay Questions and Answers 34
Short Questions and Answers 38

Paper 4 (Set 4) Long-essay Questions and Answers 49
Short Questions and Answers 53

Index *65*

DM CARDIOLOGY EXAMINATION

Paper 4 (Set 1)

LONG-ESSAY QUESTIONS AND ANSWERS

Q 1. Discuss the percutaneous management of aortic valve disease. ***(Refer 2019 MUHS)***

Ans. Percutaneous management of aortic valve disease has evolved significantly over recent years, providing less invasive alternatives to traditional surgical approaches. Here is an overview of the key techniques used:

Transcatheter Aortic Valve Replacement

Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure used primarily for patients with severe aortic stenosis who are at high risk for or are not candidates for traditional open-heart surgery. It involves the implantation of a prosthetic valve via a catheter, usually inserted through the femoral artery.

Procedure:

- *Preprocedure assessment:* Comprehensive evaluation including imaging (echocardiogram, CT scan) to determine valve anatomy and vascular access.
- *Catheter insertion:* A catheter is advanced through a small incision in the groin (or other access sites such as the subclavian artery or direct aortic access).
- *Valve deployment:* The new valve is delivered to the aortic position and deployed using a balloon or self-expanding mechanism. The old, calcified valve is typically compressed against the aortic wall.

Benefits:

- Reduced recovery time compared to open-heart surgery.
- Shorter hospital stay.
- Suitable for high-risk surgical candidates.

Considerations:

- Risk of complications such as stroke, bleeding, or vascular injury.
- Lifelong monitoring and possible need for lifelong antiplatelet therapy.
- The durability of the valve is still under evaluation, though most are performing well in mid- to long-term follow-ups.

JAYPEE BROTHERS

Percutaneous Balloon Valvuloplasty

Overview: Percutaneous balloon valvuloplasty (PBV) is a procedure used to relieve aortic stenosis by inflating a balloon within the narrowed valve to widen the opening.

Procedure:

- *Catheter insertion:* A balloon catheter is inserted via the femoral artery and advanced to the aortic valve.
- *Balloon inflation:* The balloon is inflated to stretch the valve leaflets and improve blood flow.

Benefits:

- Quick procedure with immediate symptom relief.
- Can be used as a bridge to surgery or in patients who are not candidates for surgery.

Considerations:

- Short-term relief of symptoms; does not provide a long-term solution.
- Risk of restenosis (re-narrowing of the valve) over time.
- Typically used in younger patients or those with a specific clinical scenario such as severe comorbidities or temporary relief before a more definitive procedure.

Percutaneous Valve-in-Valve Replacement

Percutaneous valve-in-valve (ViV) replacement is used for patients with a failed bioprosthetic valve in the aortic position. It involves implanting a new valve within the old, malfunctioning valve.

Procedure:

- *Catheter insertion:* Similar to TAVR, a catheter is used to deliver the new valve.
- *Deployment:* The new valve is positioned and deployed inside the old valve.

Benefits:

- Provides a treatment option for patients with failed bioprosthetic valves without the need for open-heart surgery.
- Generally associated with improved symptoms and hemodynamics.

Considerations: Similar risks to TAVR, including complications from the procedure and the durability of the new valve.

Transcatheter Aortic Valve Repair

Emerging techniques for aortic valve repair are being developed, including the use of novel devices to repair or reshape the valve rather than replacing it.

Procedure: Device deployment—devices designed to reshape or repair the aortic valve are deployed via catheter.

JAYPEE BROTHERS

Benefits:

- Potential to treat patients who are not candidates for replacement.
- Less invasive than traditional surgery.

Considerations: Still under development and not as widely available or established as TAVR.

Percutaneous management of aortic valve disease provides effective alternatives to traditional surgery, especially for high-risk or inoperable patients. TAVR remains the most common and well-established method, offering significant advantages in terms of invasiveness and recovery. Balloon valvuloplasty, valve-in-valve replacement, and emerging repair techniques offer additional options depending on patient-specific factors and valve pathology. As technology and techniques continue to evolve, these percutaneous methods are expected to improve further, broadening their application and effectiveness.

Q 2. Discuss various classification of coronary bifurcation lesions and describe various bifurcation stent implantation techniques with clinical evidence. ***(Refer 2019 MUHS)***

Ans.

Classification of Coronary Bifurcation Lesions

Coronary bifurcation lesions occur at the point where a main coronary artery divides into two branches. The classification of these lesions helps guide treatment decisions and stent implantation techniques.

Medina Classification

The Medina classification is a commonly used system that categorizes bifurcation lesions based on the involvement of the main vessel and the side branch:

- *Medina 1,1,1:* Both the main vessel and side branch ostia are involved.
- *Medina 1,0,1:* The main vessel ostium is involved, but the side branch is not.
- *Medina 0,1,1:* The side branch ostium is involved, but the main vessel is not.
- *Medina 0,0,1:* Only the side branch is involved, not the main vessel.
- *Medina 0,1,0:* Only the main vessel ostium is involved.

Douglas Classification

The Douglas classification focuses on the angle between the main vessel and side branch, and the length of the lesion:

- *Type A:* Simple bifurcation lesions with minimal angulation.
- *Type B:* Lesions with moderate angulation or stenosis of the side branch.
- *Type C:* Complex bifurcations with significant angulation or side branch involvement.

JAYPEE BROTHERS

European Bifurcation Club Classification

The European Bifurcation Club (EBC) classification evaluates bifurcations based on their anatomical complexity:

- *Type I:* Simple bifurcations with minimal lesion complexity.
- *Type II:* Intermediate complexity with side branch involvement or moderate angulation.
- *Type III:* Complex bifurcations with severe side branch involvement and challenging angulation.

Bifurcation Stent Implantation Techniques

Bifurcation lesions require specialized stenting techniques to achieve optimal outcomes. Key techniques include:

Crush Technique

Procedure:

- A stent is deployed in the main vessel first.
- A balloon is used to crush the side branch stent into the main vessel stent.
- Another balloon is used to expand the side branch stent, followed by final kissing balloon inflation.

Clinical evidence: Study—the CRUSH study showed that the crush technique is effective in reducing restenosis and improving side branch patency compared to conventional techniques.

Provisional Stenting Technique

Procedure:

- A single stent is initially deployed in the main vessel.
- The side branch is treated with balloon angioplasty if necessary.
- If the side branch remains compromised, a second stent can be deployed in a stepwise manner.

Clinical evidence: Study—the PROTECT trial demonstrated that provisional stenting is associated with lower rates of target lesion revascularization and similar outcomes compared to other bifurcation techniques.

DK Crush Technique

Procedure:

- A stent is deployed in the main vessel.
- A balloon is used to crush the side branch stent.
- After initial balloon dilation, a second balloon is used for final kissing inflation.

Clinical evidence: Study—the DKCRUSH-V study found that the DK Crush technique provides superior outcomes in terms of reduced restenosis and target lesion revascularization rates compared to the standard crush technique.

JAYPEE BROTHERS

T-stenting Technique

Procedure:

- A stent is deployed in the main vessel and a smaller stent is deployed in the side branch.
- Final kissing balloon inflation is performed to ensure optimal stent apposition.

Clinical evidence: Study—the T-stenting study indicated that this technique can be effective for certain bifurcation lesions, especially those with less severe side branch involvement.

Side Branch Stenting (SB Stenting) Technique

Procedure:

- A stent is deployed in the side branch first, followed by stenting of the main vessel if needed.
- This technique is used when the side branch is the primary lesion site.

Clinical evidence: Study—evidence is limited, but some studies suggest that SB stenting can be effective in specific scenarios, particularly where the side branch lesion is dominant.

Understanding these classifications and techniques is crucial for optimizing treatment outcomes in patients with coronary bifurcation lesions.

SHORT QUESTIONS AND ANSWERS

Q 1. Caval valve systems for tricuspid valve lesions and its mechanism of action. ***(Refer 2019 MUHS)***

Ans. The caval valve system is a specialized prosthetic valve designed for the management of tricuspid valve lesions, which can occur due to various conditions, including rheumatic heart disease, infective endocarditis, and congenital defects. These lesions can lead to significant complications such as right heart failure and systemic venous congestion.

Mechanism of Action

- *Structure and design:* The caval valve typically features a flexible, biocompatible design that mimics the natural anatomy of the tricuspid valve. This design allows for optimal blood flow dynamics and reduces the risk of thrombus formation.
- *Functionality:* The primary function of the caval valve is to facilitate unidirectional blood flow from the right atrium to the right ventricle while preventing regurgitation. It achieves this through:
  - *Leaflet coaptation:* The valve has flexible leaflets that coapt during ventricular systole, ensuring a tight seal and preventing backflow.

JAYPEE BROTHERS

  - *Hemodynamic performance:* The caval valve is designed to maintain normal hemodynamics, thus reducing the pressure in the right atrium and improving cardiac output.
- *Surgical application:* The implantation of the caval valve typically occurs during open-heart surgery. Surgeons carefully place the valve to ensure proper alignment and function, which is critical for the valve's performance.
- *Comparative advantage:* Compared to traditional mechanical valves, the caval valve system may offer improved hemodynamic performance, reduced risk of thrombosis, and lower incidence of hemolysis due to its innovative design.

In short, the caval valve system provides an effective solution for patients with severe tricuspid valve lesions by restoring normal blood flow dynamics and enhancing overall cardiac function. Its design and mechanism of action contribute to its efficacy in managing these complex cardiac conditions.

Q 2. Three-dimensional echocardiography and its use in cardiac interventions. ***(Refer 2019 MUHS)***

Ans. *Three-dimensional echocardiography (3DE)* is an advanced imaging technique that provides 3D view of the heart, offering detailed insights into cardiac anatomy and function. This technology enhances the accuracy of cardiac assessments and is particularly valuable in guiding various cardiac interventions.

Three-dimensional Echocardiography

Definition: 3DE utilizes ultrasound technology to capture and reconstruct images of the heart in three dimensions, creating a more comprehensive view compared to traditional two-dimensional echocardiography (2DE).

Key features:

- *Volume imaging:* Provides a complete view of the heart's chambers, valves, and vessels.
- *Real-time imaging:* Offers dynamic imaging capabilities to assess cardiac structures and function in real time.
- *Enhanced visualization:* Improves the assessment of complex cardiac anatomy and pathology.

Applications in Cardiac Interventions

- *Guidance in structural heart interventions:*
  - *Transcatheter aortic valve replacement:* 3DE helps in precise localization and sizing of the aortic annulus, guiding the deployment of the prosthetic valve and assessing its position and function postimplantation.

JAYPEE BROTHERS

- *Evidence:* Studies such as the PARTNER trial indicate that 3DE improves accuracy in valve sizing and positioning, leading to better clinical outcomes and reduced procedural complications.

- *Mitral valve repair/replacement:* Provides detailed views of the mitral valve anatomy, facilitating the planning and execution of repair techniques (e.g., annuloplasty) and ensuring optimal placement of prosthetic valves.
  - *Evidence:* Research has shown that 3DE enhances the assessment of mitral valve morphology and function, leading to improved outcomes in mitral valve interventions.

- *Assessment of congenital heart defects:*
  - *Complex congenital lesions:* 3DE is crucial for evaluating complex congenital heart defects, such as atrial septal defects (ASDs) and ventricular septal defects (VSDs), and planning corrective procedures.
    - *Evidence:* Studies demonstrate that 3DE provides superior anatomical detail compared to 2DE, improving the accuracy of defect assessment and intervention planning.

Guidance in Percutaneous Interventions

- *Percutaneous left atrial appendage closure (LAAC):* 3DE aids in the precise measurement and characterization of the left atrial appendage, guiding device placement and ensuring proper closure.
  - *Evidence:* Clinical studies show that 3DE reduces the risk of device malposition and improves procedural success rates in LAAC procedures.

Assessment of Cardiac Function

- *Cardiac chambers and valves:* Provides detailed views of chamber volumes, valve morphology, and function, which are critical for assessing the impact of interventions and guiding treatment decisions.
  - *Evidence:* Research highlights that 3DE offers more accurate measurements of chamber volumes and valve areas compared to 2DE, enhancing the evaluation of cardiac function and the effectiveness of interventions.

Guidance in Electrophysiology Procedures

- *Catheter ablation:* 3DE can be used to guide catheter positioning and assess anatomical structures during electrophysiology procedures, such as atrial fibrillation ablation.
  - *Evidence:* Studies suggest that integrating 3DE into electrophysiology procedures improves anatomical visualization and helps in the precise placement of ablation catheters.

JAYPEE BROTHERS

Three-dimensional echocardiography is a powerful tool in cardiac interventions, offering:

- *Enhanced visualization:* Provides detailed 3D images of cardiac structures.
- *Improved accuracy:* Aids in precise planning and execution of interventions.
- *Guidance in various procedures:* Facilitates TAVR, mitral valve repair, congenital defect correction, percutaneous interventions, and electrophysiology procedures.

Clinical evidence supports the use of 3DE in improving outcomes by enhancing anatomical assessment, guiding procedural planning, and reducing complications.

Q 3. PSCK9 inhibitors, indications and evidence. *(Refer 2019 MUHS)*

Ans. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors are a class of medications that lower low-density lipoprotein cholesterol (LDL-C) levels by inhibiting the PCSK9 protein. This protein plays a crucial role in the regulation of LDL receptors in the liver. By inhibiting PCSK9, these drugs enhance the liver's ability to clear LDL cholesterol from the bloodstream, significantly reducing the risk of cardiovascular events.

Indications

PCSK9 inhibitors are primarily indicated for the following conditions:

- *Primary hyperlipidemia:* For patients with heterozygous familial hypercholesterolemia (HeFH) or nonfamilial primary hypercholesterolemia who require additional LDL-C reduction despite maximally tolerated statin therapy.
- *Atherosclerotic cardiovascular disease (ASCVD):* For patients with a history of cardiovascular events (such as myocardial infarction or stroke) who are at high risk for future events and require further LDL-C reduction.
- *Statin intolerance:* For patients who cannot tolerate statins due to side effects, PCSK9 inhibitors can be used as an alternative to achieve LDL-C goals.
- *Additional indications:* Emerging evidence suggests potential use in patients with conditions such as diabetes, chronic kidney disease, and those at very high risk for cardiovascular disease, even if they do not meet the traditional criteria.

Evidence Supporting Use

The efficacy and safety of PCSK9 inhibitors have been demonstrated in multiple clinical trials:

- *ODYSSEY trial:* The ODYSSEY LONG TERM trial demonstrated that alirocumab (a PCSK9 inhibitor) significantly reduced LDL-C levels by

JAYPEE BROTHERS

62% compared to placebo in patients with atherosclerotic cardiovascular disease, along with a notable reduction in cardiovascular events.

- *FOURIER trial:* The FOURIER trial studied evolocumab (another PCSK9 inhibitor) in patients with established cardiovascular disease. It showed that evolocumab reduced the risk of major cardiovascular events by 15% compared to placebo, with a significant reduction in LDL-C levels.
- *Comparison with statins:* A meta-analysis of multiple studies indicated that PCSK9 inhibitors provide superior LDL-C reduction compared to statins alone and improve outcomes in high-risk populations.
- *Long-term safety:* Safety profiles from various studies have shown that PCSK9 inhibitors are generally well tolerated, with no significant increase in adverse events compared to standard lipid-lowering therapy.

PCSK9 inhibitors represent a significant advancement in the management of hyperlipidemia, particularly for patients with familial hypercholesterolemia and those at high cardiovascular risk. The accumulated evidence supports their use not only for lowering LDL-C levels but also for reducing the incidence of cardiovascular events. Their role continues to expand as further research explores their use in broader patient populations.

Q 4. NOAC trials for use with antiplatelets in post-PCI status.
(Refer 2019 MUHS)

Ans. Non-vitamin K antagonist oral anticoagulants (NOACs), also known as direct oral anticoagulants (DOACs), have gained attention in recent years for their potential use in combination with antiplatelet therapy in patients who have undergone percutaneous coronary intervention (PCI). The combination aims to reduce the risk of thromboembolic events while minimizing the risk of bleeding complications.

Trials and Evidence

- *PIONEER AF-PCI trial:*
  - This trial evaluated the efficacy and safety of rivaroxaban in combination with a P2Y12 inhibitor in patients with atrial fibrillation (AF) undergoing PCI.
  - *Results:* The trial showed that rivaroxaban, when used in a low-dose regimen (15 mg) with a P2Y12 inhibitor, reduced the incidence of major and clinically relevant nonmajor bleeding compared to the traditional triple therapy (warfarin plus dual antiplatelet therapy).
  - *Conclusion:* Rivaroxaban provides a safer alternative to warfarin in patients requiring anticoagulation post-PCI while receiving antiplatelet therapy.

JAYPEE BROTHERS

- *RE-DUAL PCI trial:*
  - This trial investigated the use of dabigatran in patients with AF undergoing PCI and receiving dual antiplatelet therapy.
  - *Results:* The study found that a strategy of dabigatran (110 mg or 150 mg) in combination with a P2Y12 inhibitor resulted in a lower risk of bleeding compared to triple therapy with warfarin and dual antiplatelet therapy. Additionally, the effectiveness in preventing thromboembolic events was comparable to that of warfarin.
  - *Conclusion:* Dabigatran can be safely used with antiplatelet agents in the post-PCI setting, providing an effective alternative to traditional anticoagulation strategies.
- *ARISTOTLE trial:*
  - While primarily focused on apixaban's role in patients with AF, this trial provided insights into the use of apixaban in combination with antiplatelet therapy in patients undergoing PCI.
  - *Results:* The trial demonstrated that apixaban was associated with a lower risk of major bleeding compared to warfarin while maintaining similar efficacy in preventing thromboembolic events.
  - *Conclusion:* Apixaban is a viable option for patients requiring anticoagulation alongside antiplatelet therapy post-PCI.
- *CANTOS trial:*
  - The CANTOS trial explored the use of canakinumab in patients with a history of myocardial infarction, with some participants also receiving anticoagulant and antiplatelet therapy. While not primarily focused on NOACs, it provides insights into the management of high-risk patients post-PCI.
  - *Results:* The trial indicated potential benefits in reducing cardiovascular events but highlighted the need for careful monitoring of bleeding risks with combined therapies.
  - *Conclusion:* Further research is needed to understand the role of NOACs in broader populations undergoing PCI, particularly those at high risk for cardiovascular events.

NOACs, including rivaroxaban, dabigatran, and apixaban, have shown promise in trials for use with antiplatelet therapy in patients post-PCI, particularly in those with atrial fibrillation or at high risk of thromboembolic events. The evidence suggests that NOACs may provide an effective and safer alternative to traditional anticoagulation strategies, significantly reducing bleeding risks while maintaining efficacy. Ongoing research and further trials will be essential to establish optimal dosing regimens and patient selection criteria for these therapies in the post-PCI setting.

JAYPEE BROTHERS

Q 5. Methods and hardware used for chronic total occlusion percutaneous coronary intervention (CTO-PCI). *(Refer 2019 MUHS)*

Ans. Chronic total occlusion of coronary arteries presents significant challenges in interventional cardiology. CTO-PCI involves specialized techniques and hardware to successfully recanalize occluded coronary arteries, restoring blood flow to the myocardium. The management of CTOs requires an understanding of various methods and the use of advanced tools to enhance procedural success.

Methods for CTO-PCI

- *Antegrade approach:*
  - *Description:* The antegrade approach involves accessing the coronary artery distal to the occlusion using standard guidewires and catheters.
  - *Techniques:*
    - *Wire escalation technique:* Utilizes progressively stiffer guidewires to navigate through the occlusion.
    - *Parallel wire technique:* Two wires are used simultaneously to create a pathway for crossing the occlusion.
- *Retrograde approach:*
  - *Description:* This method involves accessing the occluded artery from a collateral circulation, typically through a branch of another coronary artery.
  - *Techniques:*
    - *Collateral wire technique:* Uses a guidewire advanced through collateral vessels to reach the distal part of the occlusion.
    - *Retrograde ballooning:* A balloon is advanced from the retrograde access to facilitate the passage of the guidewire through the occlusion.
- *Hybrid approach:*
  - *Description:* Combines antegrade and retrograde techniques for enhanced success in complex cases.
  - *Techniques:* Involves using both access points to facilitate wire navigation and ballooning as needed.
- *Re-entry techniques:*
  - *Description:* Used when the guidewire cannot cross the occlusion.
  - *Techniques:*
    - *Intravascular ultrasound (IVUS) guidance:* Provides real-time imaging to identify the distal vessel and guide re-entry.
    - *Controlled antegrade re-entry (CAR):* Uses specialized tools to facilitate the re-entry of the guidewire into the true lumen.

JAYPEE BROTHERS

- *Use of advanced imaging:*
  - *Description:* Fluoroscopy, IVUS, and optical coherence tomography (OCT) are employed to visualize the anatomy and guide interventions.
  - *Techniques:* Advanced imaging allows for better assessment of the occlusion and surrounding structures.

Hardware Used for CTO-PCI

- *Guidewires:*
  - *Specialized CTO wires:* Stiffer and more supportive than standard guidewires, allowing for better navigation through tough fibrous tissue and calcifications.
  - *Support wires:* Provide additional stiffness and backup support during the procedure.
- *Balloon catheters:*
  - *Scoring balloons:* Equipped with tiny blades to help dilate heavily calcified lesions and facilitate wire passage.
  - *OTW (Over-the-Wire) balloons:* Used for balloon angioplasty once the guidewire crosses the occlusion.
- *Stents:*
  - *Drug-eluting stents (DES):* Utilized after successful recanalization to prevent restenosis.
  - *Bioresorbable vascular scaffolds (BVS):* Emerging option for specific cases requiring temporary support.
- *Guiding catheters:*
  - *Dedicated CTO catheters:* Designed to facilitate access to the occluded artery and provide support for complex procedures.
  - *Short sheath systems:* Allow for greater maneuverability and reduce arterial trauma.
- *Re-entry devices:*
  - *Re-entry kits:* Contain specialized tools for guiding the wire back into the true lumen after attempts at crossing the occlusion.
  - *The CrossBoss and Stingray systems:* Used for controlled re-entry into the true lumen during complex CTO interventions.
- *Imaging devices:*
  - *IVUS and OCT:* Provide detailed imaging of the coronary arteries, aiding in navigation and assessment during CTO-PCI.

CTO-PCI is a complex and evolving field that requires specialized methods and advanced hardware to achieve successful recanalization of chronic total occlusions. The combination of antegrade and retrograde techniques, along with the use of specialized guidewires, balloons, stents, and imaging tools, enhances procedural success and improves patient outcomes. As technology advances, further innovations are expected to refine CTO-PCI techniques and expand their applicability.

JAYPEE BROTHERS

Q 6. ARNI trials. ***(Refer 2019 MUHS)***

Ans. *Angiotensin receptor-neprilysin inhibitors (ARNIs)* are a class of medications used to treat heart failure with reduced ejection fraction (HFrEF). The most well-known drug in this class is *sacubitril/valsartan (Entresto)*. Various clinical trials have demonstrated the efficacy of ARNI therapy in improving outcomes for patients with heart failure. Here is a summary of the key ARNI trials:

PARADIGM-HF Trial

- *Purpose:* To evaluate the efficacy of sacubitril/valsartan (ARNI) compared to enalapril, an angiotensin-converting enzyme (ACE) inhibitor, in patients with HFrEF.
- *Design:* Randomized, double-blind, multicenter trial.
- *Participants:* 8,442 patients with symptomatic heart failure and left ventricular ejection fraction (LVEF) ≤40%.

Findings:

- *Primary endpoint:* Reduction in the composite of cardiovascular death or first hospitalization for heart failure.
  - *Results:* Sacubitril/valsartan significantly reduced the risk of cardiovascular death or hospitalization for heart failure by 20% compared to enalapril.
- *Secondary endpoints:* Improved symptoms, quality of life, and reduced overall mortality.
  - *Results:* Sacubitril/valsartan improved symptoms, quality of life, and reduced the risk of all-cause mortality.

Clinical significance: This trial established sacubitril/valsartan as a superior treatment to ACE inhibitors for reducing heart failure-related events and mortality. It led to the widespread adoption of ARNI therapy in clinical practice for patients with HFrEF.

PARAGON-HF Trial

- *Purpose:* To assess the efficacy of sacubitril/valsartan in heart failure with preserved ejection fraction (HFpEF).
- *Design:* Randomized, double-blind, multicenter trial.
- *Participants:* 4,822 patients with HFpEF and elevated natriuretic peptides.

Findings:

- *Primary endpoint:* Reduction in cardiovascular death or hospitalization for heart failure.
  - *Results:* Sacubitril/valsartan did not significantly reduce the primary composite endpoint compared to valsartan alone.

JAYPEE BROTHERS

- *Secondary endpoints:* Showed trends toward benefit in reducing cardiovascular death and heart failure hospitalization.
  - *Results:* There were modest improvements in secondary outcomes, suggesting potential benefits in specific subgroups.

Clinical significance: Although the primary endpoint was not met, the trial suggested that ARNI therapy may offer some benefit in HFpEF, particularly in patients with elevated natriuretic peptides.

LIFE Study (Long-term Study of Sacubitril/Valsartan)

- *Purpose:* To evaluate long-term safety and efficacy of sacubitril/valsartan in clinical practice.
- *Design:* Real-world, observational study.
- *Participants:* Patients with HFrEF treated with sacubitril/valsartan.

Findings:

- *Primary endpoint:* Long-term cardiovascular outcomes and safety.
  - *Results:* The study confirmed the benefits observed in the PARADIGM-HF trial, with continued reductions in heart failure hospitalization and cardiovascular mortality.

Clinical significance: The LIFE study provided real-world evidence supporting the long-term efficacy and safety of sacubitril/valsartan, reinforcing the findings of clinical trials and its role in managing HFrEF.

Summary of ARNI Trials

- *PARADIGM-HF:* Demonstrated sacubitril/valsartan's superiority over enalapril in reducing cardiovascular death and hospitalization in HFrEF.
- *PARAGON-HF:* Showed mixed results in HFpEF, with potential benefits in specific subgroups but no significant reduction in the primary endpoint.
- *LIFE study:* Provided real-world validation of the benefits and safety of sacubitril/valsartan.

ARNI therapy, particularly sacubitril/valsartan, represents a major advancement in the treatment of HFrEF, offering significant improvements in clinical outcomes. While the benefits in HFpEF are less clear, ongoing research may further elucidate the role of ARNI in this population.

JAYPEE BROTHERS

for detailed information on cardiology books, visit our website www.jaypeebrothers.com, for detailed information on cardiology books, visit our website ww

CARDIOLOGY Examination Paper
for DM (Cardiology) Students

Salient Features

- Serves as a comprehensive and reliable study companion for DM Cardiology students. Its lucid explanations, strategic organization, and relevance to the examination syllabus make it an indispensable resource for students striving to achieve excellence in their academic pursuits. It will greatly benefit the candidates preparing for the DM Cardiology university examination
- *Comprehensive coverage:* Covers a wide range of topics from congenital heart abnormalities to advanced cardiac physiology and pathology, based on previous year questions from top-notch universities
- *Exam-oriented approach:* Structured to mirror the DM Cardiology examination format with long-essay and short questions and answers for effective preparation
- *Clinical correlations:* Provides practical insights and correlations to real-world scenarios to reinforce understanding
- *In-depth discussions:* Detailed explanations aid comprehension of complex concepts, making it suitable for learning and revision.

Barun Kumar MD DM (Cardiology) is an Additional Professor and Interventional Cardiologist, Department of Cardiology, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India. He is recognized for his role in the establishment of the Department of Cardiology at AIIMS, Rishikesh. He completed DM (Cardiology) from Dr Ram Manohar Lohia Hospital, New Delhi, India. He has been engaged in many teaching endeavors over the past 11 years. For the past 6 years, he has been instructing and educating students in the field of DM Cardiology. He has more than 85 national and international publications including book chapters. He has a particular inclination for teaching. He possesses extensive knowledge and experience in the domain of interventional cardiology.

Printed in India

Available at all medical bookstores or buy online at www.ejaypee.com

JAYPEE BROTHERS
Medical Publishers (P) Ltd.
EMCA House, 23/23-B, Ansari Road,
Daryaganj, New Delhi - 110 002, INDIA
www.jaypeebrothers.com

Join us on facebook.com/JaypeeMedicalPublishers
Follow us on instagram.com/JaypeeMedicalPublishers

Shelving Recommendation
CARDIOLOGY

ISBN 978-93-5696-914-8